IPIC2023, organized by the International Patient Organization for Primary Immunodeficiencies (IPOPI) and now at its 6th edition, has established itself as one of the leading international congresses in the PIDs clinical landscape with a unique approach to its scientiﬁc program underpinned by its focus on patient-centeredness.
This year Kedrion’s participation includes an international delegation of 30 clinicians (including Italy, Serbia, Poland, Turkey, and Portugal) and an exhibition booth.
Our commitment goes beyond this Congress with long-lasting partnerships around the world.
Kedrion shares IPOPI’s commitment in improving access to early diagnosis and treatment through advocacy and awareness, promoting knowledge and data sharing to increase understanding of PID, improve clinical care and advance the research, and finally strengthen cooperation among multi-stakeholder to optimize all programs and activities worldwide.
One of the past highlights of our collaboration was the release of “4ID”, a multilingual IPOPI App designed by patients for patients, which aims to help them organize and keep track of their health in a simple and innovative way.
In Italy we support, through an unconditional contribution, the project “SIDE BY SIDE: Lives in the mirror and (extra)ordinary stories about Primary Immunodeficiencies” project, a narrative medicine initiative conceived and implemented by the Primary Immunodeficiencies Association (AIP O.d.V.). The project aims to share the extraordinary and touching experiences of six patients and their referring physicians.
Watch the video-stories here: www.aip-it.org/i-nostri-progetti/affianco/
In the US we recently announced our support to the Immune Deficiency Foundation (IDF) Research Grant Program for the second year in a row. The IDF Research Grant Program is designed to encourage and support patient-oriented research on primary immunodeficiencies (PIs), including well-defined research projects with a specific benefit to improve treatment, health, management, or diagnosis of people with Primary Immunodeficiencies.